US 11,891,373 B2
Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Eric Christian Hansen, Pawcatuck, CT (US); Christopher Scott Seadeek, West Lafayette, IN (US); and Anil Mahadeo Rane, Mystic, CT (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by PFIZER INC., New York, NY (US)
Filed on Oct. 6, 2021, as Appl. No. 17/494,938.
Application 17/494,938 is a division of application No. 16/521,742, filed on Jul. 25, 2019, granted, now 11,168,066.
Application 16/521,742 is a continuation of application No. 15/567,433, granted, now 10,414,748, issued on Sep. 17, 2019, previously published as PCT/IB2016/052107, filed on Apr. 13, 2016.
Claims priority of provisional application 62/152,108, filed on Apr. 24, 2015.
Prior Publication US 2022/0024894 A1, Jan. 27, 2022
Int. Cl. C07D 401/04 (2006.01); A61K 31/4439 (2006.01)
CPC C07D 401/04 (2013.01) [A61K 31/4439 (2013.01); C07B 2200/13 (2013.01)] 7 Claims
 
1. A crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea imidazole complex (1:1), having the structure:

OG Complex Work Unit Chemistry